Shire acquires Methypatch
Executive Summary
Shire acquires worldwide sales & marketing rights to the pending attention deficit and hyperactivity disorder treatment Methypatch from Noven. The company expects future Methypatch (methylphenidate transdermal) sales to offset generic erosion of Adderall (amphetamine). Barr's ANDA for Adderall was approved Feb. 11 (1"The Pink Sheet" Feb. 10, p. 29). "Shire will make an upfront payment to Noven of $25 mil. followed by separate milestone payments up to $125 mil., which will be dependent on FDA approval and the achievement of certain sales targets," company said. Methypatch has an estimated user fee goal of June 2003...
You may also be interested in...
Tidbits From The Fourth Quarter Calls, In Brief
AstraZeneca Prilosec generic erosion: AstraZeneca's Prilosec holds 47% share of total prescriptions following generic omeprazole entry in late 2002, CFO Jon Symonds says on Jan. 30 investor call. "We must, of course, be cautious with only six weeks of data available...but it's clear that the erosion rate is significantly less than that observed with either Prozac or Zestril at a similar stage, seemingly consistent with Kudco's inability to fully supply the market." Schwarz' subsidiary Kudco is distributing generic Prilosec on a limited basis due to supply constraints (1"The Pink Sheet" Dec. 16, 2002, p. 30)....Nexium ramp-up: Nexium total prescription share is over 20%, up more than eight percentage points in 2002. Share of total scripts written by gastrointestinal specialists is more than 27%...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.